Rep. Gilbert Cisneros Acquires STERIS Shares

Congressman Gilbert Cisneros made a purchase of STERIS plc shares valued between $1,001 and $15,000 on May 13, 2026. This transaction was reported on June 9, 2026, as part of the STOCK Act filings that disclose trades made by U.S. politicians after they occur.

STERIS plc Stock Down 11.7%

Shares of NYSE:STE traded near $207.56 recently. STERIS plc, with a market cap of about $20.23 billion, has a P/E ratio of 26.17 and a forward P/E of 17.14, indicating investor expectations for future growth. The stock has traded between $195.14 and $269.44 over the past year. Its 50-day moving average sits at $215.95, while the 200-day moving average is $239.71. The company's current ratio is 2.09, and its quick ratio is 1.34, suggesting a solid liquidity position. STERIS also maintains a debt-to-equity ratio of 29.

Other Institutional Activity in STERIS

In recent institutional activity, BlackRock, Inc. reduced its holdings by 14,812 shares, ending with 9,026,621 shares valued at approximately $1.99 billion. Vanguard Capital Management LLC established a new position with 6,366,378 shares worth about $1.41 billion. Meanwhile, State Street Corp increased its stake by 377,028 shares to a total of 4,991,868 shares, valued at $1.10 billion. Morgan Stanley also boosted its holdings by 554,445 shares, now owning 4,394,263 shares worth around $971.7 million.

Recent Earnings

STERIS reported revenue of $5.94 billion, reflecting a growth of 7.3%. The company's net margin stands at 13.2%, with a return on equity of 11.37%. Earnings per share (EPS) are reported at $7.93. The next earnings release is expected on August 5, 2026.

Dividend

The company offers an annual dividend rate of $2.52, yielding about 1.21%. The dividend payout ratio is 31%, indicating a balanced approach to returning capital to shareholders while retaining earnings for growth.

Insider Buying and Selling at STERIS plc

Insider transactions at STERIS have seen several executives sell shares recently. President and CEO Daniel Carestio sold 1,374 shares on June 5, 2026, at an average price of $212 under a planned sale. Other executives, including Julia Madsen and Kenneth Kohler, sold shares on June 4, 2026, at similar prices, but these were not planned sales.

Analysts Set New Price Targets

On May 13, 2026, Keybanc maintained its buy rating on STERIS with a price target of $269. The consensus among analysts is a buy recommendation, with a mean target price of $256.86, based on seven analyst opinions.

About STERIS plc

STERIS plc, headquartered in Mentor, Ohio, provides infection prevention products and services globally. It operates through segments like Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers a wide range of products, from cleaning chemistries to surgical tables and sterilization equipment. Under the leadership of CEO Daniel A. Carestio, STERIS serves healthcare providers and manufacturers of medical devices and pharmaceuticals, employing around 17,937 people.

Bottom Line

Gilbert Cisneros's recent purchase of STERIS shares highlights ongoing interest in the company's stock, which has shown resilience and growth potential in the healthcare sector. Investors often track such transactions for insights, although 13F filings and STOCK Act disclosures are backward-looking and may not reflect current positions. STERIS's stable financials and analyst endorsements suggest continued attention from the market.